Julie Wolf leads bio and health investing at 2048 Ventures, focusing on platform technologies for human health. She previously served as Chief Science Officer at IndieBio New York, co-founded Brooklyn Bio, and communicated microbiology research at the American Society for Microbiology.
Julie Wolf leads bio and health investing at 2048 Ventures, focusing on platform technologies for human health. She previously served as Chief Science Officer at IndieBio New York, co-founded Brooklyn Bio, and communicated microbiology research at the American Society for Microbiology.
Career
Julie Wolf holds a PhD, Microbiology, Immunology, and Cancer Biology from University of Minnesota and a BS, Microbiology from University of Michigan.
Partner at 2048 Ventures from 2024-04 to PresentNBBoard Member at Nionyx Bio until Present
IChief Science Officer, New York at IndieBio from 2021-08 to 2022-02Served on the founding team of SOSV's New York biotech accelerator, helping early-stage science companies develop and communicate their work.
ASScience Communications Specialist at American Society for Microbiology from 2015-10 to 2020-02Communicated microbiology research through writing, social media and live programming; hosted Meet the Microbiologist.
AEPostdoctoral Research Fellow at Albert Einstein College of Medicine from 2010-06 to 2015-06Researched fungal pathogenesis, medical mycology and infectious disease in Arturo Casadevall's group.
Investing Announcements
Cosigns Received
Daniella CohenPrincipal at 2048 Ventures
and pushing me to give it my all.
Alex IskoldFounder and Partner at 2048 Ventures
Zann and Julie are both committed, selfless, no ego, and fully dedicated to excellence in everything they undertake.